entitygenericstock-market
Replimune
Notes
Replimune
One-line summary: Oncolytic-immunotherapy biotech (ticker REPL); RP1 refile in the FDA-right-shift basket after a prior CRL.
What it is
Oncolytic virus immunotherapy company; lead asset RP1, previously issued a Complete Response Letter under the old FDA.
Why it matters to stock-market
A lateral tradeable in fda-right-shift-to-rare-disease-refile-rerate — analysts put its probability-of-success "well above 50%" on the more permissive FDA posture.
Key facts
- Ticker: REPL (NASDAQ)
Sources
Related
Referenced by